Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers

Figures

• 

  Figure 1.. Changes in Amyloid-β (Aβ) Blood Biomarkers Following Sacubitril/Valsartan Treatment Plasma biomarker values were log10-transformed, with error bars indicating the SE of the adjusted between-group difference for each biomarker at each time point. Dotted lines represent the baseline as a reference. Relative differences in the sacubitril/valsartan group compared with the valsartan group was 31% for Aβ42, 93% for Aβ, and 32% for the ratio of Aβ42 to Aβ40 (all P < .001). LSM indicates least squares mean.

• 

  Figure 2.. Changes in Other Blood Biomarkers Following Sacubitril/Valsartan Treatment Plasma biomarker values were log10-transformed, and error bars indicate the SE of the adjusted between-group difference for each biomarker at each time point. Dotted lines represent the baseline as a reference. No significant differences were observed for phosphorylated tau at threonine 181 (p-tau181) (2.5%; 95% CI, −13.9% to 22.1%; P = .78), phosphorylated tau at threonine 217 (p-tau217) (−7.1%; 95% CI, −15.8% to 2.4%; P = .14), glial fibrillary acidic protein (GFAP) (−1.5%; 95% CI, −10.8% to −8.8%; P = .77), or neurofilament light (NfL) (3.2%; 95% CI, −9.7% to 17.9%; P = .65).